scholarly journals Immune Responses to Small Nuclear Ribonucleoproteins: Antigen-Dependent Distinct B Cell Epitope Spreading Patterns in Mice Immunized with Recombinant Polypeptides of Small Nuclear Ribonucleoproteins

2002 ◽  
Vol 168 (10) ◽  
pp. 5326-5332 ◽  
Author(s):  
Umesh S. Deshmukh ◽  
Carol C. Kannapell ◽  
Shu Man Fu
2009 ◽  
Vol 61 (2) ◽  
pp. 333-336 ◽  
Author(s):  
Andreas Recke ◽  
Christian Rose ◽  
Enno Schmidt ◽  
Eva-Bettina Bröcker ◽  
Detlef Zillikens ◽  
...  

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Koemchhoy Khim ◽  
Yong Jun Bang ◽  
Sao Puth ◽  
Yoonjoo Choi ◽  
Youn Suhk Lee ◽  
...  

AbstractFlagellin, a protein-based Toll-like receptor agonist, is a versatile adjuvant applicable to wide spectrum of vaccines and immunotherapies. Given reiterated treatments of immunogenic biopharmaceuticals should lead to antibody responses precluding repeated administration, the development of flagellin not inducing specific antibodies would greatly expand the chances of clinical applications. Here we computationally identified immunogenic regions in Vibrio vulnificus flagellin B and deimmunized by simply removing a B cell epitope region. The recombinant deimmunized FlaB (dFlaB) maintains stable TLR5-stimulating activity. Multiple immunization of dFlaB does not induce FlaB-specific B cell responses in mice. Intranasally co-administered dFlaB with influenza vaccine enhanced strong Ag-specific immune responses in both systemic and mucosal compartments devoid of FlaB-specific Ab production. Notably, dFlaB showed better protective immune responses against lethal viral challenge compared with wild type FlaB. The deimmunizing B cell epitope deletion did not compromise stability and adjuvanticity, while suppressing unwanted antibody responses that may negatively affected vaccine antigen-directed immune responses in repeated vaccinations. We explain the underlying mechanism of deimmunization by employing molecular dynamics analysis.


2015 ◽  
Vol 163 (1) ◽  
pp. 56-68 ◽  
Author(s):  
Caleb Cornaby ◽  
Lauren Gibbons ◽  
Vera Mayhew ◽  
Chad S. Sloan ◽  
Andrew Welling ◽  
...  

1998 ◽  
Vol 164 (1) ◽  
pp. 185-200 ◽  
Author(s):  
Judith A. James ◽  
John B. Harley

2002 ◽  
Vol 70 (7) ◽  
pp. 3479-3492 ◽  
Author(s):  
Ivette Caro-Aguilar ◽  
Alexandra Rodríguez ◽  
J. Mauricio Calvo-Calle ◽  
Fanny Guzmán ◽  
Patricia De la Vega ◽  
...  

ABSTRACT Clinical trials of malaria vaccines have confirmed that parasite-derived T-cell epitopes are required to elicit consistent and long-lasting immune responses. We report here the identification and functional characterization of six T-cell epitopes that are present in the merozoite surface protein-1 of Plasmodium vivax (PvMSP-1) and bind promiscuously to four different HLA-DRB1∗ alleles. Each of these peptides induced lymphoproliferative responses in cells from individuals with previous P. vivax infections. Furthermore, linear-peptide chimeras containing the promiscuous PvMSP-1 T-cell epitopes, synthesized in tandem with the Plasmodium falciparum immunodominant circumsporozoite protein (CSP) B-cell epitope, induced high specific antibody titers, cytokine production, long-lasting immune responses, and immunoglobulin G isotype class switching in BALB/c mice. A linear-peptide chimera containing an allele-restricted P. falciparum T-cell epitope with the CSP B-cell epitope was not effective. Two out of the six promiscuous T-cell epitopes exhibiting the highest anti-peptide response also contain B-cell epitopes. Antisera generated against these B-cell epitopes recognize P. vivax merozoites in immunofluorescence assays. Importantly, the anti-peptide antibodies generated to the CSP B-cell epitope inhibited the invasion of P. falciparum sporozoites into human hepatocytes. These data and the simplicity of design of the chimeric constructs highlight the potential of multimeric, multistage, and multispecies linear-peptide chimeras containing parasite promiscuous T-cell epitopes for malaria vaccine development.


Sign in / Sign up

Export Citation Format

Share Document